AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32469870 — intervention group
Group type: EXPERIMENTAL
Intervention: Food supplement from mid-gestation to term (MG-T)
Number of subjects: 460
Study 32469870 — intervention group
Group type: COMPARATOR
Intervention: Routine prenatal care (RPC)
Number of subjects: 460
Study 34476629 — intervention group
Group type: EXPERIMENTAL
Intervention: M1 a‐tDCS concurrent with physical therapy (PT) for 10 sessions of 20 minutes each
Number of subjects: 32
Study 34476629 — intervention group
Group type: COMPARATOR
Intervention: Sham group received sham tDCS concurrent with physical therapy (PT) for 10 sessions of 20 minutes each
Number of subjects: 32
Study 34476629 — intervention group
Group type: COMPARATOR
Intervention: Control group received only physical therapy (PT) for 10 sessions of 20 minutes each
Number of subjects: 32
Study 33975039 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus coagulans (5 × 10^9 CFU/kg)
Number of subjects: 480
Study 32004709 — intervention group
Group type: EXPERIMENTAL
Intervention: TeenBP CDS
Number of subjects: 925
Study 33573502 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesthetic-experiential learning (KEL) group
Number of subjects: 42
Study 33573502 — intervention group
Group type: COMPARATOR
Intervention: Model-mastery learning (MML) group
Number of subjects: 42
Study 33958657 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly iron-folic acid supplementation (WIFAS)
Number of subjects: 226
Study 33958657 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 226
Study 32162567 — intervention group
Group type: EXPERIMENTAL
Intervention: End-fire biopsy
Number of subjects: 730
Study 32162567 — intervention group
Group type: COMPARATOR
Intervention: Side-fire biopsy
Number of subjects: 730
Study 35073890 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Remote Interpreting (VR)
Number of subjects: 305
Study 35073890 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone Remote Interpreting (TR)
Number of subjects: 305
Study 35073890 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 305
Study 33780432 — intervention group
Group type: COMPARATOR
Intervention: Conventional training (CT)
Number of subjects: 83
Study 33780432 — intervention group
Group type: COMPARATOR
Intervention: Eating training (ET)
Number of subjects: 83
Study 33780432 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive swallowing training (IST)
Number of subjects: 83
Study 36070638 — intervention group
Group type: EXPERIMENTAL
Intervention: Solriamfetol 37.5 mg/day (OSA only), 75 mg/day, 150 mg/day, 300 mg/day
Number of subjects: 710
Study 36070638 — intervention group
Group type: EXPERIMENTAL
Intervention: Solriamfetol (combined doses)
Number of subjects: 710
Study 36070638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 710
Study 35217575 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent ieramilimab
Number of subjects: 255
Study 35217575 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ieramilimab and spartalizumab
Number of subjects: 255
Study 32002617 — intervention group
Group type: EXPERIMENTAL
Intervention: PICC
Number of subjects: 59
Study 32002617 — intervention group
Group type: COMPARATOR
Intervention: PORT
Number of subjects: 59
Study 34518266 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control (systolic BP target <120 mm Hg, n=2371)
Number of subjects: 4733
Study 34518266 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure control (systolic BP target <140 mm Hg, n=2362)
Number of subjects: 4733
Study 34518266 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure treatment with standard glycaemic control
Number of subjects: 4733
Study 34518266 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure treatment with standard glycaemic control
Number of subjects: 4733
Study 34518266 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure treatment with intensive glycaemic control
Number of subjects: 4733
Study 34518266 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure treatment with intensive glycaemic control
Number of subjects: 4733
Study 34518266 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure treatment for those with cognitive impairment
Number of subjects: 4733
Study 34518266 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure treatment for those with cognitive impairment
Number of subjects: 4733
Study 34518266 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure treatment for those with normal cognitive function
Number of subjects: 4733
Study 34518266 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure treatment for those with normal cognitive function
Number of subjects: 4733
Study 32360887 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Care Professional (HCP) support
Number of subjects: 292
Study 32360887 — intervention group
Group type: EXPERIMENTAL
Intervention: HCP Plus Peer support
Number of subjects: 292
Study 32360887 — intervention group
Group type: COMPARATOR
Intervention: HCP support
Number of subjects: 292
Study 32360887 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver outcomes
Number of subjects: 292
Study 35802187 — intervention group
Group type: EXPERIMENTAL
Intervention: THA assisted by a newly designed robotic arm
Number of subjects: 72
Study 35802187 — intervention group
Group type: COMPARATOR
Intervention: THA with conventional surgical methods
Number of subjects: 72
Study 32915300 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESPB) with 20 mL of 0.375% levobupivacaine
Number of subjects: 45
Study 32915300 — intervention group
Group type: COMPARATOR
Intervention: Retrolaminar block (RLB) with 20 mL of 0.375% levobupivacaine
Number of subjects: 45
Study 32915300 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESPB)
Number of subjects: 45
Study 32915300 — intervention group
Group type: COMPARATOR
Intervention: Retrolaminar block (RLB)
Number of subjects: 45
Study 32401339 — intervention group
Group type: EXPERIMENTAL
Intervention: PACES intervention (n = 49)
Number of subjects: 101
Study 32401339 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (n = 52)
Number of subjects: 101
Study 35616265 — intervention group
Group type: EXPERIMENTAL
Intervention: Real MWM group (n = 25)
Number of subjects: 50
Study 35616265 — intervention group
Group type: COMPARATOR
Intervention: Sham MWM group (n = 25)
Number of subjects: 50
Study 33175346 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 10
Study 32140719 — intervention group
Group type: EXPERIMENTAL
Intervention: Seabuckthorn oil augmented in 16:1n-7t (480 mg 16:1n-7t/d)
Number of subjects: 13
Study 32140719 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmodified seabuckthorn oil (1520 mg 16:1n-7c/d)
Number of subjects: 13
Study 32140719 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 13
Study 36000599 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of processed food 1 or 2 times a month
Number of subjects: 90
Study 36000599 — intervention group
Group type: EXPERIMENTAL
Intervention: Processed food consumption
Number of subjects: 90
Study 36000599 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflatoxin M1 levels in breast milk
Number of subjects: 90
Study 34462346 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient pulmonary rehabilitation (PR)
Number of subjects: 701
Study 34462346 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient pulmonary rehabilitation (PR)
Number of subjects: 701
Study 34462346 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in ?80% of planned outpatient PR sessions
Number of subjects: 701
Study 32397802 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde Intrarenal Surgery (RIRS)
Number of subjects: 132
Study 32397802 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous Nephrolithotomy (PNL)
Number of subjects: 132
Study 32397802 — intervention group
Group type: COMPARATOR
Intervention: PNL
Number of subjects: 132
Study 32397802 — intervention group
Group type: EXPERIMENTAL
Intervention: RIRS
Number of subjects: 132
Study 36239033 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (2 mg/day, adjusted to 1-10 mg/day)
Number of subjects: 41
Study 36239033 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 41
Study 36239033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 32940187 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (monoclonal antibody against IL-6 receptors)
Number of subjects: 0
Study 32940187 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 0
Study 32958010 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitally supported intervention for clinical decision making in polypharmacy
Number of subjects: 27
Study 32958010 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 27
Study 37815091 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Exercise (RE) 2×/week
Number of subjects: 33
Study 37815091 — intervention group
Group type: EXPERIMENTAL
Intervention: High Protein Diet via Whey Protein Supplementation (PRO, 2 × 25 g whey protein isolate/d)
Number of subjects: 33
Study 37815091 — intervention group
Group type: EXPERIMENTAL
Intervention: RE + PRO
Number of subjects: 33
Study 37815091 — intervention group
Group type: COMPARATOR
Intervention: Control (CON, 2 × 23.75 g maltodextrin/d)
Number of subjects: 33
Study 33683019 — intervention group
Group type: EXPERIMENTAL
Intervention: Peramivir 600 mg repeat-dose
Number of subjects: 208
Study 33683019 — intervention group
Group type: EXPERIMENTAL
Intervention: Peramivir 300 mg single-dose
Number of subjects: 208
Study 33683019 — intervention group
Group type: COMPARATOR
Intervention: Oseltamivir
Number of subjects: 208
Study 35036430 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized nutritional intervention
Number of subjects: 100
Study 35036430 — intervention group
Group type: COMPARATOR
Intervention: Regular intervention (Control)
Number of subjects: 100
Study 33956063 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermic intraperitoneal chemotherapy (HIPEC)
Number of subjects: 0
Study 33032651 — intervention group
Group type: EXPERIMENTAL
Intervention: Pessary self-management
Number of subjects: 330
Study 33032651 — intervention group
Group type: COMPARATOR
Intervention: Clinic-based care
Number of subjects: 330
Study 35465686 — intervention group
Group type: EXPERIMENTAL
Intervention: MK‐7 (720 µg) plus vitamin D (25 µg)
Number of subjects: 365
Study 35465686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 365
Study 33908729 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated approach to the management of hypertension through the Campania Salute Network
Number of subjects: 15000
Study 35959357 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster nursing combined with CDT
Number of subjects: 84
Study 35959357 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing combined with CDT
Number of subjects: 84
Study 34282987 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVT)
Number of subjects: 560
Study 34282987 — intervention group
Group type: COMPARATOR
Intervention: Medical management (MM)
Number of subjects: 560
Study 34261972 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (under 40 years)
Number of subjects: 128
Study 34261972 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (above 40 years)
Number of subjects: 128
Study 34261972 — intervention group
Group type: COMPARATOR
Intervention: Group 1 and Group 2
Number of subjects: 128
Study 33269529 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% minoxidil
Number of subjects: 54
Study 33269529 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 54
Study 34849957 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/daclatasvir 400/60 mg once-daily
Number of subjects: 1083
Study 34849957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1083
Study 34103634 — intervention group
Group type: EXPERIMENTAL
Intervention: GWAS analysis of asthma-associated loci
Number of subjects: 56167
Study 34103634 — intervention group
Group type: EXPERIMENTAL
Intervention: TWAS analysis for lung tissue
Number of subjects: 56167
Study 34103634 — intervention group
Group type: EXPERIMENTAL
Intervention: TWAS analysis for blood tissue
Number of subjects: 56167
Study 34103634 — intervention group
Group type: EXPERIMENTAL
Intervention: Prioritization of druggable genes
Number of subjects: 56167
Study 32674048 — intervention group
Group type: EXPERIMENTAL
Intervention: 15‐mg oral methotrexate per week
Number of subjects: 33
Study 32674048 — intervention group
Group type: COMPARATOR
Intervention: 3–5‐mg/kg/day cyclosporine
Number of subjects: 33
Study 35657955 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates training group (n = 14)
Number of subjects: 28
Study 35657955 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 14)
Number of subjects: 28
Study 32991792 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepines with escitalopram for GAD
Number of subjects: 640
Study 32991792 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepines with venlafaxine for MDD
Number of subjects: 640
Study 35100916 — intervention group
Group type: EXPERIMENTAL
Intervention: Real Age feedback (younger)
Number of subjects: 0
Study 35100916 — intervention group
Group type: EXPERIMENTAL
Intervention: Real Age feedback (slightly older)
Number of subjects: 0
Study 35100916 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no Real Age feedback)
Number of subjects: 0
Study 35100916 — intervention group
Group type: EXPERIMENTAL
Intervention: Real Age feedback (much younger)
Number of subjects: 0
Study 35100916 — intervention group
Group type: EXPERIMENTAL
Intervention: Real Age feedback (much older)
Number of subjects: 0
Study 33411006 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 Diabetes (T1D)
Number of subjects: 11313
Study 33411006 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 Diabetes (T2D)
Number of subjects: 11313
Study 33411006 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 11313
Study 32182190 — intervention group
Group type: EXPERIMENTAL
Intervention: Kripalu Yoga program
Number of subjects: 53
Study 32182190 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 53
Study 35080487 — intervention group
Group type: EXPERIMENTAL
Intervention: Added soda
Number of subjects: 36
Study 35080487 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% fruit juice
Number of subjects: 36
Study 35080487 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 36
Study 33934389 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol (1000 mg/day)
Number of subjects: 11
Study 33934389 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 11
Study 33420829 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral cooling device (ICD) set to 8 °C
Number of subjects: 20
Study 33420829 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral cooling device (ICD) set to 15 °C
Number of subjects: 20
Study 33420829 — intervention group
Group type: COMPARATOR
Intervention: Intraoral cooling device (ICD)
Number of subjects: 20
Study 32149617 — intervention group
Group type: COMPARATOR
Intervention: FMS patients
Number of subjects: 0
Study 32149617 — intervention group
Group type: COMPARATOR
Intervention: CFS patients
Number of subjects: 0
Study 32149617 — intervention group
Group type: COMPARATOR
Intervention: Matched healthy individuals
Number of subjects: 0
Study 35763658 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 5 mg
Number of subjects: 140
Study 35763658 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg
Number of subjects: 140
Study 33744810 — intervention group
Group type: EXPERIMENTAL
Intervention: Training Program MOTIVA (16 hours initial course + online activities for 12 months + Problem Based Interviewing with expert feedback)
Number of subjects: 54
Study 33744810 — intervention group
Group type: COMPARATOR
Intervention: Control Group (no training)
Number of subjects: 54
Study 33744810 — intervention group
Group type: EXPERIMENTAL
Intervention: Training Program MOTIVA (12 months follow-up)
Number of subjects: 54
Study 36181304 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg/day placebo
Number of subjects: 49
Study 36181304 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/day melatonin
Number of subjects: 49
Study 36181304 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/day melatonin plus 30 min of bright light therapy (BLT)
Number of subjects: 49
Study 33539612 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral or mediolateral episiotomy
Number of subjects: 63654
Study 33539612 — intervention group
Group type: COMPARATOR
Intervention: No episiotomy
Number of subjects: 63654
Study 33339415 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated nutrition behavior change interventions
Number of subjects: 340
Study 33339415 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 340
Study 35580595 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-handed mask holding
Number of subjects: 80
Study 35580595 — intervention group
Group type: COMPARATOR
Intervention: One-handed mask holding
Number of subjects: 80
Study 34301645 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of older children in the home
Number of subjects: 357
Study 34301645 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooking outside the home
Number of subjects: 357
Study 34301645 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted incidence of childhood injury
Number of subjects: 357
Study 34301645 — intervention group
Group type: EXPERIMENTAL
Intervention: Common mechanisms of injury
Number of subjects: 357
Study 34301645 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group differences in mechanism of injury
Number of subjects: 357
Study 34301645 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender differences in injury incidence
Number of subjects: 357
Study 34301645 — intervention group
Group type: EXPERIMENTAL
Intervention: Common modifiable risk factors (stove height, fuel type, secured cabinets)
Number of subjects: 357
Study 35700691 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilastine 20 mg under fasting conditions
Number of subjects: 24
Study 35700691 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilastine 20 mg under fed conditions
Number of subjects: 24
Study 33189179 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestogen-only pill (75 μg desogestrel) plus a rapid access card to a sexual and reproductive health clinic
Number of subjects: 636
Study 33189179 — intervention group
Group type: COMPARATOR
Intervention: Control group advised to attend their usual contraceptive provider
Number of subjects: 636
Study 32975923 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofascial dextrose prolotherapy (8 mL of 12.5% dextrose and 40 mg of 2% lidocaine, injected 2 times with 1-week interval)
Number of subjects: 66
Study 32975923 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofascial dextrose prolotherapy
Number of subjects: 66
Study 32975923 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy (superficial heat, transcutaneous electrical nerve stimulation, pulsed ultrasound, and exercise program, 10 sessions of 30 minutes for 3 weeks)
Number of subjects: 66
Study 33059233 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound biofeedback during contractions
Number of subjects: 32
Study 33059233 — intervention group
Group type: COMPARATOR
Intervention: Standard contractions
Number of subjects: 32
Study 33059233 — intervention group
Group type: COMPARATOR
Intervention: Golf-setup position
Number of subjects: 32
Study 33059233 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 32
Study 35571644 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 80
Study 35571644 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 80
Study 34939872 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in coping skills and coping with stress self-efficacy (15 sessions, twice per week for 8 weeks)
Number of subjects: 14
Study 34939872 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological therapy (control group)
Number of subjects: 14
Study 35696234 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball attachment (Group A)
Number of subjects: 80
Study 35696234 — intervention group
Group type: EXPERIMENTAL
Intervention: Locator attachment (Group B)
Number of subjects: 80
Study 32949140 — intervention group
Group type: EXPERIMENTAL
Intervention: Seletalisib 45 mg/day
Number of subjects: 27
Study 32949140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 33412997 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) started from 40% of MIP, given in addition to a neurodevelopmental treatment program for 5 days a week for 6 weeks
Number of subjects: 21
Study 33412997 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IMT), received the same neurodevelopmental treatment program
Number of subjects: 21
Study 33412997 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 21
Study 33710385 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 1800
Study 33710385 — intervention group
Group type: COMPARATOR
Intervention: PCI
Number of subjects: 1800
Study 33710385 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD status
Number of subjects: 1800
Study 33710385 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG vs PCI in COPD patients
Number of subjects: 1800
Study 33710385 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG vs PCI in non-COPD patients
Number of subjects: 1800
Study 33710385 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment effect of CABG vs PCI
Number of subjects: 1800
Study 32286711 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Aerobic Training (CAT)
Number of subjects: 87
Study 32286711 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Aerobic Training (IAT)
Number of subjects: 87
Study 32286711 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 87
Study 35291433 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (10 mg)
Number of subjects: 41